Case Study in Environmental Medicine: Ethylene Glycol/Propylene Glycol Toxicity

Course: WB4342
CE Original Date: March 20, 2020
CE Renewal Date: March 20, 2022
CE Expiration Date: March 20, 2024

Program Description
This educational case study document is one in a series of self-instructional publications designed to increase the primary care provider’s knowledge of hazardous substances in the environment and to promote the adoption of medical practices that aid in the evaluation and care of potentially exposed patients.

Training Objectives:
At the conclusion of the session, the participant will be able to:

  1. Describe the properties of ethylene glycol.
  2. Identify sources of ethylene glycol exposure.
  3. Identify the most common route of exposure to ethylene glycol that results in toxicity in the general U.S. population.
  4. Identify who is at risk of exposure to ethylene glycol.
  5. Describe current U.S. regulations and guidelines for ethylene glycol exposure.
  6. Explain the major pathway of ethylene glycol metabolism in the body.
  7. Describe the toxicological effects of ethylene glycol poisoning.
  8. Describe what is included in the initial history and physical examination of patients potentially exposed to ethylene glycol.
  9. Describe how the clinical presentation changes over time.
  10. Identify the abnormal laboratory findings associated with ethylene glycol poisoning.
  11. List three measurements that can assist with diagnosis of ethylene glycol poisoning.
  12. Describe treatment strategies for managing ethylene glycol poisoning cases.
  13. Describe the uses of propylene glycol.
  14. Explain the potential risk of propylene glycol toxicity.
  15. Describe self-care and clinical follow-up instructions for patients exposed to ethylene glycol or propylene glycol.
  16. Describe how to improve collaborative practice across the healthcare team regarding the diagnosis and treatment of EGPG exposure.

To access the CSEM Ethylene Glycol/Propylene Glycol Toxicity, please visit the Ethylene Glycol/Propylene Glycol Toxicity case study pdf icon[PDF – 911 KB].

Faculty/Credentials
Dianyi WU,
Environmental Health Scientist
Office of Capacity Development and Applied Prevention Science (OCDAPS)
Agency for Toxic Substances and Disease Registry (ATSDR)

Who is this training for?
Physicians, Registered Nurses, Health Educators and other health professionals

Continuing Education

Accreditation Council for Continuing Medical Education (ACCME)

In support of improving patient care, The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American Academy of Physicians Assistants (AAPA), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME: The Centers for Disease Control and Prevention designates this enduring activity for a maximum of 1.75 hours AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention designates this activity for 1.75 hours nursing contact hours.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.2 hours CEU’s for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 1.5 hours total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 1.5 hours. Continuing Competency credits available are 1.5 CDC provider number 98614.

For Certified Public Health Professionals (CPH)

The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 2.0 hours CPH recertification credits for this program.

Instructions for Obtaining Continuing Education (CE)
In order to receive continuing education (CE) for WB4342 ATSDR CSEM: Ethylene Glycol/Propylene Glycol Toxicity please visit TCEO and follow these 9 Simple Steps before March 20, 2024.

Complete the activity WB4342 ATSDR CSEM: Ethylene Glycol/Propylene Glycol Toxicity
Complete the Evaluation at www.cdc.gov/GetCE
Pass the posttest at ___80___% at www.cdc.gov/GetCE

To receive free continuing education, please visit the CSEM Ethylene Glycol/Propylene Glycol Toxicity registration page.

To access the CSEM Ethylene Glycol/Propylene Glycol Toxicity, please visit the Ethylene Glycol/Propylene Glycol Toxicity case study pdf icon[PDF – 911 KB].

Training Module Information
Prerequisites:
A basic knowledge of medicine or related basics of human health promotion at a professional level is desired. The participant is expected to complete the Posttest. The participant must pass the Posttest with a score of 80% or higher. One re-take is allowed. If participants fall below 80% on the retake, they must redo CSEM Ethylene Glycol/Propylene Glycol Toxicity course if they are seeking continuing education credits. The participant may then complete a course evaluation and print out their certificate of completion

Hardware/Software:
Computer Hardware; Internet Connection Browser

Materials:
None

Format:
This activity is Web-based

DISCLOSURE:
In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies during the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, and content experts wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.

Contact Information
Debra Joseph
Environmental Medicine and Health Systems Intervention Section
Office of Capacity Development and Applied Prevention Science
Agency for Toxic Substances and Disease Registry
DOJ7@cdc.gov, (770) 488-0715

Page last reviewed: March 25, 2022